Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Klinikum Der Universität München maintains a patent portfolio in the Biotechnology & Pharmaceuticals technology area. The portfolio currently has 1 pending office action. This activity is confined to 1 distinct examiner and a distinct art unit, reflecting a focused prosecution effort. Such a structure is common for academic or clinical institutions that target specific medical innovations for patent protection.
SWIFT, CANDICE LEE serves as the busiest examiner for the portfolio, holding the busiest examiner pending office action. In the context of Biotechnology & Pharmaceuticals, this single pending matter represents the current interface between the institution and the patent office. The progress of the portfolio relies on the resolution of this action by the assigned examiner. Practitioners should be aware that the lack of diversification across examiners or art units means that the institution's patent strategy is currently tied to a single administrative path. This makes the specific feedback from SWIFT, CANDICE LEE particularly critical for the institution's intellectual property objectives.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SWIFT, CANDICE LEE | 1 | 56.6% | +37.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17920606 | COMPOSITION COMPRISING A DNA-DEGRADING ENZYME FOR USE IN A METHOD FOR THE TREATMENT OF IMMUNOSUPPRESSION AFTER ACUTE TISSUE INJURY | SWIFT, CANDICE LEE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17920606 | COMPOSITION COMPRISING A DNA-DEGRADING ENZYME FOR USE IN A METHOD FOR THE TREATMENT OF IMMUNOSUPPRESSION AFTER ACUTE TISSUE INJURY | SWIFT, CANDICE LEE | — |
| Art Unit | Apps |
|---|---|
| 1657 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17920606 | COMPOSITION COMPRISING A DNA-DEGRADING ENZYME FOR USE IN A METHOD FOR THE TREATMENT OF IMMUNOSUPPRESSION AFTER ACUTE TISSUE INJURY | SWIFT, CANDICE LEE | 1657 | §102§112 | Final Rejection | — | Pending | Oct 21, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialKlinikum Der Universität München has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Candice Lee Swift has the most, with 1 of Klinikum Der Universität München's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
